Results 131 to 140 of about 24,893 (251)

Factor H gene variants in Japanese: Its relation to atypical hemolytic uremic syndrome [PDF]

, 2011
Mutations and polymorphisms of factor H gene (FH1) are known to be closely involved in the developmentof atypical hemolytic uremic syndrome (aHUS). Several groups have identified disease risk mutations andpolymorphisms of FH1 for the development of aHUS,
Fujihara Noriko, Hidaka Yoshihiko, Hirota-Kawadobora Masako, Honda Takayuki, Koike Kenichi, Kubota Seiko, Matsuda Kazuyuki, Mukai Saki, Takezawa Yuka, Yamauchi Kazuyoshi, 山内 一由   +10 more
core   +1 more source

[Hemolytic uremic syndrome with an atypical presentation].

Revue medicale de Liege, 2010
The hemolytic uremic syndrome (HUS) is rare and of guarded prognosis in adults. It expresses a renal thrombotic microangiopathy. We report the case of a young patient whose clinical presentation and exploration make a diagnosis of HUS likely. The atypical presentation provides an opportunity not only to discuss all diagnostic elements based on recent ...
NOGUE KAMDJE, Alain, BRASSEUR, Edmond, fournier,, D'Orio, Vincenzo   +3 more
openaire   +2 more sources

Shiga toxin/verocytotoxin-producing Escherichia coli infections: practical clinical perspectives [PDF]

, 2014
Escherichia coli strains that produce Shiga toxins/verotoxins are rare, but important, causes of human disease. They are responsible for a spectrum of illnesses that range from the asymptomatic to the life-threatening hemolytic-uremic ...
Davis, T. K, Tarr, Phillip I, Van De Kar, Nicole C.A. J   +2 more
core   +2 more sources

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Journal of the American Society of Nephrology, 2019
BACKGROUND Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence rates after kidney transplant, with devastating outcomes. In late 2011, experts in France recommended the use of highly individualized complement blockade-based ...
J. Zuber, Marie Frimat, S. Caillard, N. Kamar, P. Gatault, F. Petitprez, L. Couzi, N. Jourde-Chiche, V. Châtelet, Raphaël Gaisne, D. Bertrand, J. Bamoulid, Magali Louis, R. Sberro Soussan, D. Navarro, P. Westeel, L. Frimat, C. Colosio, A. Thierry, J. Rivalan, L. Albano, N. Arzouk, E. Cornec-Le Gall, G. Claisse, M. Elias, K. El Karoui, S. Chauvet, J. Coindre, J. Rerolle, L. Tricot, J. Sayegh, C. Garrouste, C. Charasse, Yahsou Delmas, Z. Massy, M. Hourmant, A. Servais, C. Loirat, F. Fakhouri, C. Pouteil‐Noble, M. Peraldi, C. Legendre, E. Rondeau, M. Le Quintrec, V. Frémeaux-Bacchi   +44 more
semanticscholar   +1 more source

Complement System Part II: Role in Immunity [PDF]

, 2015
International audienceThe complement system has been considered for a long time as a simple lytic cascade, aimed to kill bacteria infecting the host organism.
Fremeaux-Bacchi, Veronique, Halbwachs-Mecarelli, Lise, Merle, Nicolas S., Noe, Remi, Roumenina, Lubka T.   +4 more
core   +6 more sources

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

BMC Nephrology, 2019
BackgroundThere are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with ...
J. Menne, Yahsou Delmas, F. Fakhouri, C. Licht, Åsa Lommelé, E. Minetti, F. Provôt, E. Rondeau, N. Sheerin, Jimmy Wang, L. Weekers, L. Greenbaum   +11 more
semanticscholar   +1 more source

An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment

Hematology Reports, 2018
Atypical hemolytic uremic syndrome is a rare and progressive disease caused by uncontrolled alternative complement activation. Dysregulatıon of the complement activation results in thrombotic microangiopathy and multiorgan damage.
Serife Solmaz Medeni, Sinem Namdaroglu, Tugba Cetintepe, Can Ozlu, Funda Tasli, Zehra Hilal Adibelli, Oktay Bilgir, Erhan Tatar   +7 more
doaj   +1 more source

When the environment and mutations affect organ systems [PDF]

, 2017
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) with a genetic predisposition. Like other TMAs, it presents clinically with thrombocytopenia and microangiopathic hemolytic anemia, which is accompanied by disruption of
Abu Ghanimeh, Mouhanna, Abughanimeh, Omar, Qasem, Abdulraheem, Qasrawi, Ayman   +3 more
core   +1 more source

Complement regulator CD46: Genetic variants and disease associations [PDF]

, 2015
Membrane cofactor protein (MCP; CD46) is an ubiquitously expressed complement regulatory protein that protects host cells from injury by complement.
Atkinson, John P, Liszewski, M. Kathryn
core   +2 more sources

Atypical Hemolytic‐Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment

Therapeutic apheresis and dialysis, 2018
Atypical hemolytic uremic syndrome (aHUS), a rare variant of thrombotic microangiopathy, is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment.
R. Raina, Vinod Krishnappa, T. Blaha, T. Kann, W. Hein, Linda Burke, A. Bagga   +6 more
semanticscholar   +1 more source